C12N 2830/52
Encoding ribozyme for self-inactivation
Official title: encoding ribozyme for self-inactivation
C12N2830/52 (Encoding ribozyme for self-inactivation) appears on 13 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 18
- Assignees
- 22
- Inventors
- 66
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 0 |
| 2003 | 2 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 2 | 2 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 4 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Aptamer and ribozyme equilibrium shifting (ARES) RNA circuits and uses thereof7 Jul 2026US 12,674,171 B2Trustees of Boston University
- Hepatitis A virus preparation method and hepatitis A virus prepared according to method24 Feb 2026US 12,558,417 B2SK Bioscience Co., Ltd.
- Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes15 Jul 2025US 12,359,199 B2Meiragtx UK II Limited
- Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes29 Nov 2022US 11,512,310 B2Meiragtx UK II Limited
- Viral vectors for prophylaxis and therapy of hemoglobinopathies26 Apr 2022US 11,311,632 B2Cornell University
- RNA Having Lariat-Cap Structure For Improving Intracellular Stability And Biogenesis Of mRNA, And Use Thereof8 Jan 2026US 2026/0009042 A1Korea Advanced Institute of Science and Technology
- Aptamer and ribozyme equilibrium shifting (ares) rna circuits and uses thereof2 Oct 2025US 2025/0304975 A1Trustees of Boston University
- Hepatitis a virus preparation method and hepatitis a virus prepared according to method29 May 2025US 2025/0170234 A1SK Bioscience Co., Ltd.
- Compositions and methods for screening cis regulatory elements30 Jan 2025US 2025/0034556 A1The Broad Institute, Inc.
- Compositions and methods for production of circular nucleic acid molecules9 Jan 2025US 2025/0011767 A1Circularis Biotechnologies, Inc.
Most cited
By later US patents
- .alpha.(1,3) galactosyltransferase negative porcine cells62US 6,153,428 ABioTransplant, Inc. · 2000
- Synthesis, deprotection, analysis and purification for RNA and ribozymes49US 6,437,117 B1Ribozyme Pharmaceuticals, Inc. · 2002
- Synthesis, deprotection, analysis and purification of RNA and ribozymes31US 6,649,751 B2Sirna Therapeutics, Inc. · 2003
- α(1,3) galactosyltransferase negative porcine cells27US 6,413,769 B1The General Hospital Corporation · 2002
- Synthesis, deprotection, analysis and purification of RNA and ribozymes20US 5,977,343 ARibozyme Pharmaceuticals, Inc. · 1999